Course of Hyperkalemia in Patients on Hemodialysis
Table 2
Risk of predialysis sK+ concentration >5.5 or >6.0 mmol/L at LIDI visits during the 4-week evaluation period following the initial hyperkalemic event.
LIDI visit
Predialysis sK+ at randomization (visit 4, day 1) (mmol/L)
<5.5, n = 14
5.5 to <6.0, n = 37
6.0 to <6.5, n = 21
≥6.5, n = 14
Incidence of predialysis sK + >5.5 mmol/L
Visit 12 (day 36)
8/13 (61.5)
19/33 (57.6)
10/18 (55.6)
11/13 (84.6)
Visit 13 (day 43)
4/12 (33.3)
18/33 (54.5)
15/20 (75.0)
10/13 (76.9)
Visit 14 (day 50)
5/12 (41.7)
23/33 (69.7)
17/21 (81.0)
12/13 (92.3)
Visit 15 (day 57)
5/14 (35.7)
24/33 (72.7)
13/21 (61.9)
8/12 (66.7)
Overall
22/51 (43.1)
84/132 (63.6)
55/80 (68.8)
41/51 (80.4)
Incidence of predialysis sK + >6.0 mmol/L
Visit 12 (day 36)
2/13 (15.4)
3/33 (9.1)
4/18 (22.2)
8/13 (61.5)
Visit 13 (day 43)
1/12 (8.3)
4/33 (12.1)
6/20 (30.0)
6/13 (46.2)
Visit 14 (day 50)
3/12 (25.0)
10/33 (30.3)
9/21 (42.9)
10/13 (76.9)
Visit 15 (day 57)
2/14 (14.3)
10/33 (30.3)
2/21 (9.5)
7/12 (58.3)
Overall
8/51 (15.7)
27/132 (20.5)
21/80 (26.3)
31/51 (60.8)
Data are shown as the number (%) of hyperkalemic events. Hyperkalemia was defined as sK+ >5.5 or >6.0 mmol/L after the LIDI. No imputation of missing data was conducted. For each randomization predialysis sK+ subgroup, the probability of whether patients with hyperkalemia will be hyperkalemic (sK+ >5.5 or >6.0 mmol/L) at subsequent visits was calculated as follows: [Number of hyperkalemic events/total number of possible hyperkalemic events based on patients with evaluable data] × 100. LIDI, long interdialytic interval; sK+, serum potassium.